As of June 24, 2025, PeptiDream Inc (4587.T) reports a ROE (Return on Equity) of 26.45%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of PeptiDream Inc's ROE (Return on Equity)
Over recent years, PeptiDream Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 26.45% |
| 2023-12-31 | 7.52% |
| 2022-12-31 | 23.58% |
| 2021-12-31 | 10.15% |
| 2020-12-31 | 20.97% |
This slight upward trend highlights how PeptiDream Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing PeptiDream Inc's ROE (Return on Equity) to Peers
To better understand PeptiDream Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| PeptiDream Inc (4587.T) | 26.45% |
| Sinocelltech Group Ltd (688520.SS) | 79.46% |
| Alphamab Oncology (9966.HK) | 9.08% |
| GNI Group Ltd (2160.T) | 3.01% |
| Takara Bio Inc (4974.T) | 0.90% |
| Trans Genic Inc (2342.T) | 0.07% |
Compared to its competitors, PeptiDream Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.